0001209191-22-038241.txt : 20220621 0001209191-22-038241.hdr.sgml : 20220621 20220621081512 ACCESSION NUMBER: 0001209191-22-038241 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220617 FILED AS OF DATE: 20220621 DATE AS OF CHANGE: 20220621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kay Mark A CENTRAL INDEX KEY: 0001752537 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 221026127 MAIL ADDRESS: STREET 1: 610 MAIN STREET STREET 2: 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-17 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001752537 Kay Mark A C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVE, FLOOR 2 LEXINGTON MA 02421 1 0 0 0 Stock Option (right to buy) 0.38 2022-06-17 4 A 0 12500 0.00 A 2032-06-17 Common Stock 12500 12500 D The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy. The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. /s/ Andrea Paul, as Attorney-in-Fact 2022-06-21